Moreover, in recent years, the treatment of NSCLC has made considerable progress, especially the molecular targeted therapy, including EGFR, PD‐L1, ALK, and anti‐angiogenesis inhibitors.2, 3, 4, 5 The present research aimed to explore the molecular mechanisms and to provide a new molecular therapeutic target for NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.